Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Robert Rubens"'
Autor:
Diane Stephenson, Robert Alexander, Varun Aggarwal, Reham Badawy, Lisa Bain, Roopal Bhatnagar, Bastiaan R. Bloem, Babak Boroojerdi, Jackson Burton, Jesse M. Cedarbaum, Josh Cosman, David T. Dexter, Marissa Dockendorf, E. Ray Dorsey, Ariel V. Dowling, Luc J. W. Evers, Katherine Fisher, Mark Frasier, Luis Garcia-Gancedo, Jennifer C. Goldsack, Derek Hill, Janice Hitchcock, Michele T. Hu, Michael P. Lawton, Susan J. Lee, Michael Lindemann, Ken Marek, Nitin Mehrotra, Marjan J. Meinders, Michael Minchik, Lauren Oliva, Klaus Romero, George Roussos, Robert Rubens, Sakshi Sadar, Joseph Scheeren, Eiichi Sengoku, Tanya Simuni, Glenn Stebbins, Kirsten I. Taylor, Beatrice Yang, Neta Zach
Publikováno v:
Digital Biomarkers, Vol 4, Iss 1, Pp 28-49 (2020)
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disease continuu
Externí odkaz:
https://doaj.org/article/02833b80db5e4df4916766e3401c1666
Publikováno v:
Parkinson's Disease, Vol 2018 (2018)
Background. IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD). Following an initial peak at about one hour, plasma LD concentrations are maintained for about 4-5 hours. Objective. To present dosing factors that may aff
Externí odkaz:
https://doaj.org/article/af023c1b3f40448db84bb68b8f17e3af
Autor:
Michael Lindemann, Robert Alexander, Babak Boroojerdi, Jackson Burton, Marissa F. Dockendorf, Lisa J. Bain, Jesse M. Cedarbaum, George Roussos, Eiichi Sengoku, Joseph Scheeren, Kirsten I. Taylor, Diane Stephenson, Klaus Romero, Nitin Mehrotra, Josh Cosman, Beatrice T. Yang, Robert Rubens, Varun Aggarwal, Marjan J. Meinders, Janice Hitchcock, Ariel V. Dowling, Mark Frasier, Tanya Simuni, Neta Zach, Ken Marek, Sakshi Sadar, Jennifer C. Goldsack, Michele T.M. Hu, Katherine J. Fisher, Michael P. Lawton, Derek L. G. Hill, David T. Dexter, Reham Badawy, Luis Garcia-Gancedo, Luc J.W. Evers, Bastiaan R. Bloem, Michael Minchik, Glenn T. Stebbins, Roopal Bhatnagar, E. Ray Dorsey, Lauren Oliva, Susan J. Lee
Publikováno v:
Digital Biomarkers, 4, 28-49
Digital Biomarkers, Vol 4, Iss 1, Pp 28-49 (2020)
Digital Biomarkers, 4, 1, pp. 28-49
Digit Biomark
Digital Biomarkers, Vol 4, Iss 1, Pp 28-49 (2020)
Digital Biomarkers, 4, 1, pp. 28-49
Digit Biomark
Contains fulltext : 229477.pdf (Publisher’s version ) (Open Access) Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinso
Publikováno v:
Ethicshuman researchReferences. 43(5)
At electronic dance music events in Belgium in 2013 to 2015, seemingly intoxicated patients were included without their informed consent in an observational toxicology study when the attending physicians determined that they needed treatment with an
Publikováno v:
Clinical Neuropharmacology
Objectives IPX203 is an investigational oral extended-release capsule formulation of carbidopa and levodopa. The pharmacodynamics and efficacy of IPX203 were compared with immediate-release carbidopa-levodopa (IR CD-LD) in this open-label, rater-blin
Autor:
Sherron Kell, Suneel K. Gupta, Robert Rubens, Sarita Khanna, Peter A. LeWitt, Leo Verhagen Metman
Publikováno v:
Clinical Neuropharmacology
Objectives Extended-release (ER) carbidopa-levodopa (CD-LD) (IPX066/RYTARY/NUMIENT) produces improvements in "off" time, "on" time without troublesome dyskinesia, and Unified Parkinson Disease Rating Scale scores compared with immediate-release (IR)
Autor:
David L. Kreitzman, Robert Rubens, Anette Nieves, Ann Hsu, Robert A. Hauser, James W. Tetrud, Aaron Ellenbogen, Sherron Kell, Grace S. Liang, Sarita Khanna, Eric S. Farbman, Paul A. Nausieda, Suneel K. Gupta, Andrew P. Duker
Publikováno v:
Journal of the Neurological Sciences. 373:116-123
Background IPX066 (Rytary®; carbidopa and levodopa [CD-LD] extended-release capsules) was designed to achieve therapeutic LD plasma concentrations within 1 h of dosing and maintain LD concentrations for a prolonged duration in early or advanced Park
Publikováno v:
Clinical Neuropharmacology
OBJECTIVE IPX203 is an investigational oral extended-release capsule formulation of carbidopa-levodopa (CD-LD). The aim of this study was to characterize the single-dose pharmacodynamics, pharmacokinetics, and safety of IPX203 in subjects with advanc
Autor:
Ramon Gil, Ann Hsu, Nishit B. Modi, Sarita Khanna, Carlos Singer, J Spiegel, Lawrence Elmer, Paul A. Nausieda, Robert Rubens, Suneel K. Gupta, Sherron Kell
Publikováno v:
Journal of Parkinson's Disease
Background Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD co
Autor:
Daniel K. Burns, Jingtao Wu, Rebecca Evans, James R. Burke, Kathleen A. Welsh-Bohmer, Ann M. Saunders, Robert Alexander, Carl Chiang, Meredith Culp, Emilianelo Ratti, Michael W. Lutz, Brenda L. Plassman, Robert Rubens
Publikováno v:
Alzheimer's & Dementia. 15:P1488-P1489